Yoshihiro Inamoto
A5026533672- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Childhood Cancer Survivors' Quality of Life
- Chronic Lymphocytic Leukemia Research
- T-cell and B-cell Immunology
- Chronic Myeloid Leukemia Treatments
- Renal Transplantation Outcomes and Treatments
- Polyomavirus and related diseases
- Lymphoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Cytomegalovirus and herpesvirus research
- Corneal Surgery and Treatments
- Mesenchymal stem cell research
- Transplantation: Methods and Outcomes
- Viral-associated cancers and disorders
- Ocular Surface and Contact Lens
- Neutropenia and Cancer Infections
- Vector-Borne Animal Diseases
- Systemic Sclerosis and Related Diseases
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
Fujita Health University
2024-2025
Fujita Health University Hospital
2025
National Cancer Center
2016-2023
Fred Hutch Cancer Center
2012-2022
Tokyo National Hospital
2014-2022
Markey Cancer Center
2022
University of Kentucky
2022
Cleveland Clinic
2022
Vanderbilt University Medical Center
2022
Baylor College of Medicine
2022
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity chronic graft-versus-host disease (GVHD). 2014 NIH consensus maintains framework prior with further refinement based on evidence. Revisions have been made to address areas controversy or confusion, such as overlap GVHD subcategory distinction between active past tissue damage. Diagnostic involvement mouth, eyes, genitalia, lungs revised. Categories should be defined...
Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) time. This study used central database Center for International Blood Marrow Transplant Research (CIBMTR) to describe time cGVHD incidence, nonrelapse mortality, risk factors cGVHD. The 12-year period was divided into 3 intervals, 1995 1999, 2000 2003, 2004 2007, included 26,563 patients with acute leukemia, myeloid...
In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease (GVHD) Consensus Response Criteria Working Group recommended several measures to document serial evaluations chronic GVHD organ involvement. Provisional definitions complete response, partial and progression were proposed for each overall outcome. Based on publications over last 9 years, 2014 has updated its recommendations interpretation responses. Major changes include elimination clinical parameters from...
Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (HCT) is associated with high mortality. We hypothesized that inhaled fluticasone, azithromycin, and montelukast (FAM) a brief steroid pulse could avert progression of new-onset BOS. tested this in phase II, single-arm, open-label, multicenter study (NCT01307462). Thirty-six patients were enrolled within 6 months BOS diagnosis. The primary endpoint was treatment failure, defined as 10% or greater...
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications transplantation, availability alternative donor sources, less toxic preparative regimens, new manipulation techniques, novel GVHD prevention methods, all which have expanded the applicability procedure. These advances led to clinical practice conundrums when...
Several distinct graft-versus-host disease (GVHD)-related syndromes have been defined by the National Institutes of Health Consensus Conference. We enrolled a prospective cohort 911 hematopoietic cell transplantation (HCT) recipients at 13 centers between March 2011 and May 2014 to evaluate 4 GVHD syndromes: late acute (aGVHD), chronic (cGVHD), bronchiolitis obliterans syndrome, cutaneous sclerosis. The median age HCT was 53.7 years. majority patients received peripheral blood stem...
Our objective was to describe the incidence of nonmalignant late complications and their association with health functional status in a recent cohort hematopoietic cell transplantation (HCT) survivors.We determined 14 effects adults who underwent from January 2004 through June 2009 at Fred Hutchinson Cancer Research Center survived least 1 year after HCT. Data were derived review medical records annual self-reported questionnaires.The 1,087 survivors study had median age HCT 53 years (range,...
To determine the influence of modifiable lifestyle factors on risk cardiovascular disease after hematopoietic cell transplantation (HCT).HCT survivors ≥ 1 year treated from 1970 to 2010 (n = 3,833) were surveyed 2011 current health and related (smoking, diet, recreational physical activity). Responses 2,362) compared with those a matched general population sample (National Health Nutrition Examination Survey [NHANES]; n 1,192).Compared NHANES participants, HCT (median age, 55.9 years; median...
Knowing the impact of chronic graft-versus-host disease (GVHD) on quality life (QoL) after allogeneic hematopoietic stem cell transplantation (allo-HCT) by GVHD type and severity is critical for providing care to transplant survivors. We conducted a cross-sectional questionnaire study examine relationship between patient-reported QoL as measured Medical Outcomes Study 36-Item Short-Form Health Survey, Functional Assessment Cancer Therapy-Bone Marrow Transplant, visual analogue scale (VAS)...
Over the past 2 decades, reduced-intensity conditioning allogeneic hematopoietic cell transplantation (RIC HCT) has increased substantially. Many patients do not have fully HLA-matched donors, and impact of HLA mismatch on RIC HCT been examined in large cohorts. We analyzed 2588 recipients 8/8 HLA-high resolution matched (n = 2025) or single-locus mismatched 563) unrelated donor (URD) from 1999 to 2011. Overall survival (OS) was primary outcome. Secondary endpoints included treatment-related...
Abstract The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes HCT approaches by donor adults with ALL in remission. primary objective was to compare overall survival (OS) among HCTs PTCy and HLA-matched sibling (MSD), 8/8 unrelated (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing MSD HCT,...
The American Society for Transplantation and Cellular Therapy (ASTCT) published its guidelines on indications autologous allogeneic hematopoietic cell transplantation (HCT) immune effector therapy (IECT) in 2020. Since then we have witnessed rapid advancements the field of IECT, resulting several new chimeric antigen receptor T-cell (CAR-T) products disease being approved by U.S. Food Drug Administration (FDA). To keep abreast these practice changes, ASTCT Committee Practice Guidelines...
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment for myelofibrosis. However, optimal conditioning regimen either with reduced-intensity (RIC) or myeloablative (MAC) is not well known. Using Center International Blood and Marrow Transplant Research database, we identified adults aged ≥18 years myelofibrosis undergoing allo-HCT between 2008-2019 analyzed outcomes separately in RIC MAC cohorts based on regimens used. Among 872 eligible patients, 493...
Chronic GVHD was recognized as a complication of allogeneic hematopoietic cell transplantation more than 30 years ago, but progress has been slowed by the limited insight into pathogenesis disease and mechanisms that lead to development immunological tolerance. Only 6 randomized phase III treatment studies have reported. Results retrospective prospective II clinical trials suggested overall benefit from with mycophenolate mofetil or thalidomide, these results were not substantiated initial...